newsfilter
← Latest News
GlobeNewswire·

Replimune to Present at Two Upcoming Investor Conferences

WOBURN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members